Literature DB >> 25120049

Use of a claims database to characterize and estimate the incidence rate for Castleman disease.

Nikhil Munshi1, Maneesha Mehra, Helgi van de Velde, Avinash Desai, Ravi Potluri, Jessica Vermeulen.   

Abstract

Castleman disease (CD) is a rare lymphoproliferative disorder affecting single (unicentric; UCD) or multiple (multicentric; MCD) lymph nodes. The incidence of this difficult to diagnose disease is poorly understood, as no International Classification of Diseases, Ninth Revision (ICD-9) code is available. This study utilized a unique strategy to estimate its incidence using two commercial claims databases, IMS LifeLink™ and Truven Health Analytics MarketScan(®). Patients with an index diagnosis of lymphadenopathy (ICD-9 code 785.6) were followed longitudinally for 1 year prior to and 2 years post-index diagnosis date. An algorithm that identifies potential patients with CD was developed to determine the incidence rate in person-years. The incidence rate for CD was calculated as 21 (IMS LifeLink™) and 25 (MarketScan(®)) per million person-years. Additionally, 23% of patients with CD were identified as potentially suffering from MCD. These results are consistent with the definition of an orphan disease, and the low incidence of the disease estimated in the literature.

Entities:  

Keywords:  Castleman disease; incidence; multicentric Castleman disease

Mesh:

Year:  2014        PMID: 25120049     DOI: 10.3109/10428194.2014.953145

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  51 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

Review 2.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions.

Authors:  Xiaosheng Fang; Zhongling Sun; Zijun Y Xu-Monette; Ken H Young
Journal:  Oncologist       Date:  2020-11-30

Review 4.  TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.

Authors:  Gordan Srkalovic; Inga Marijanovic; Maya B Srkalovic; David C Fajgenbaum
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

5.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

6.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

Review 7.  Review of siltuximab in the treatment of multicentric Castleman's disease.

Authors:  Shayna Sarosiek; Ruchit Shah; Nikhil C Munshi
Journal:  Ther Adv Hematol       Date:  2016-06-23

Review 8.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

9.  Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.

Authors:  Jenna Sopfe; Ashley Endres; Kristen Campbell; Kari Hayes; Andrew T Trout; Xiayuan Liang; Robert Lorsbach; Maureen M O'Brien; Carrye R Cost
Journal:  Pediatr Blood Cancer       Date:  2019-01-24       Impact factor: 3.167

10.  A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment.

Authors:  Dan Yang; Xuan Zhou; Youcai Zhao; Shibin Cao; Ailing Su; Xuezhong Zhang; Yanli Xu; Xiuqun Zhang
Journal:  Cancer Biol Ther       Date:  2018-04-30       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.